A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors (Q33410836)

26 July 2017

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors (English)

1 reference

26 July 2017

13

George Wilding

1 reference

26 July 2017

Dustin A Deming

1

1 reference

26 July 2017

Jacob Ninan

2

1 reference

26 July 2017

Howard H Bailey

3

1 reference

26 July 2017

Jill M Kolesar

4

1 reference

26 July 2017

Jens Eickhoff

5

1 reference

26 July 2017

Joel M Reid

6

1 reference

26 July 2017

Matthew M Ames

7

1 reference

26 July 2017

Renee M McGovern

8

1 reference

26 July 2017

Dona Alberti

9

1 reference

26 July 2017

Rebecca Marnocha

10

1 reference

26 July 2017

Igor Espinoza-Delgado

11

1 reference

26 July 2017

John Wright

12

1 reference

26 July 2017

William R Schelman

14

1 reference

26 July 2017

10 October 2013

1 reference

26 July 2017

7

1 reference

Investigational New Drugs

inferred from page(s)

published in

1 reference

26 July 2017

32

1 reference

26 July 2017

2

1 reference

26 July 2017

323-329

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-0035-8

26 July 2017

0 references

cites work

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Cancer genetics and epigenetics: two sides of the same coin?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Epigenetic drivers of genetic alterations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Histone deacetylase inhibitors: Potential in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Epigenetics and cancer, 2nd IARC meeting, Lyon, France, 6 and 7 December 2007.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Worms gang up on bacteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Alteration of nucleosome structure as a mechanism of transcriptional regulation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-013-0035-8

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-013-0035-8

Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3949160

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24114123

12 December 2020

inferred from PubMed ID database lookup

Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24114123

12 December 2020

inferred from PubMed ID database lookup

The fundamental role of epigenetic events in cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24114123

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-013-0035-8

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference